$CRSP CRISPR Therapeutics AG Insider Trading Week 36/2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in CRISPR Therapeutics AG.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in CRISPR Therapeutics AG in week 36/2017.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Versant Venture Capital IV, L. ... | 10% Owner | Sell | J | 0.00 | 1,240 | 0 | 0 | 1.2 K to 0 (-100.00 %) |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Versant Venture Capital IV, L. ... | 10% Owner | Buy | J | 0.00 | 1,240 | 0 | 1,240 | 0 to 1.2 K |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Versant Venture Capital IV, L. ... | 10% Owner | Sell | J | 0.00 | 17,283 | 0 | 0 | 17.3 K to 0 (-100.00 %) |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Versant Venture Capital IV, L. ... | 10% Owner | Buy | J | 0.00 | 17,283 | 0 | 17,283 | 0 to 17.3 K |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Versant Venture Capital IV, L. ... | 10% Owner | Sell | J | 0.00 | 292,529 | 0 | 0 | 292.5 K to 0 (-100.00 %) |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Versant Venture Capital IV, L. ... | 10% Owner | Buy | J | 0.00 | 292,529 | 0 | 292,529 | 0 to 292.5 K |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Versant Venture Capital IV, L. ... | 10% Owner | Sell | J | 0.00 | 26,491 | 0 | 52,987 | 79.5 K to 53 K (-33.33 %) |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Versant Venture Capital IV, L. ... | 10% Owner | Sell | J | 0.00 | 61,993 | 0 | 123,994 | 186 K to 124 K (-33.33 %) |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Versant Venture Capital IV, L. ... | 10% Owner | Sell | J | 0.00 | 23,899 | 0 | 47,801 | 71.7 K to 47.8 K (-33.33 %) |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Versant Venture Capital IV, L. ... | 10% Owner | Sell | J | 0.00 | 814,599 | 0 | 1,629,204 | 2.4 M to 1.6 M (-33.33 %) |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Versant Venture Capital IV, L. ... | 10% Owner | Sell | J | 0.00 | 8,110 | 0 | 16,224 | 24.3 K to 16.2 K (-33.33 %) |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Versant Venture Capital IV, L. ... | 10% Owner | Sell | J | 0.00 | 1,368,013 | 0 | 2,736,032 | 4.1 M to 2.7 M (-33.33 %) |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Buy | J | 0.00 | 9,918 | 0 | 9,918 | 0 to 9.9 K |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | J | 0.00 | 1,240 | 0 | 0 | 1.2 K to 0 (-100.00 %) |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Buy | J | 0.00 | 1,240 | 0 | 1,240 | 0 to 1.2 K |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | J | 0.00 | 17,283 | 0 | 0 | 17.3 K to 0 (-100.00 %) |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Buy | J | 0.00 | 17,283 | 0 | 17,283 | 0 to 17.3 K |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | J | 0.00 | 292,529 | 0 | 0 | 292.5 K to 0 (-100.00 %) |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Buy | J | 0.00 | 292,529 | 0 | 292,529 | 0 to 292.5 K |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | J | 0.00 | 26,491 | 0 | 52,987 | 79.5 K to 53 K (-33.33 %) |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | J | 0.00 | 61,993 | 0 | 123,994 | 186 K to 124 K (-33.33 %) |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | J | 0.00 | 23,899 | 0 | 47,801 | 71.7 K to 47.8 K (-33.33 %) |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | J | 0.00 | 814,599 | 0 | 1,629,204 | 2.4 M to 1.6 M (-33.33 %) |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | J | 0.00 | 8,110 | 0 | 16,224 | 24.3 K to 16.2 K (-33.33 %) |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | J | 0.00 | 1,368,013 | 0 | 2,736,032 | 4.1 M to 2.7 M (-33.33 %) |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Buy | J | 0.00 | 55,447 | 0 | 55,447 | 0 to 55.4 K |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | J | 0.00 | 1,240 | 0 | 0 | 1.2 K to 0 (-100.00 %) |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Buy | J | 0.00 | 1,240 | 0 | 1,240 | 0 to 1.2 K |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | J | 0.00 | 17,283 | 0 | 0 | 17.3 K to 0 (-100.00 %) |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Buy | J | 0.00 | 17,283 | 0 | 17,283 | 0 to 17.3 K |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | J | 0.00 | 292,529 | 0 | 0 | 292.5 K to 0 (-100.00 %) |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Buy | J | 0.00 | 292,529 | 0 | 292,529 | 0 to 292.5 K |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | J | 0.00 | 26,491 | 0 | 52,987 | 79.5 K to 53 K (-33.33 %) |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | J | 0.00 | 61,993 | 0 | 123,994 | 186 K to 124 K (-33.33 %) |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | J | 0.00 | 23,899 | 0 | 47,801 | 71.7 K to 47.8 K (-33.33 %) |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | J | 0.00 | 814,599 | 0 | 1,629,204 | 2.4 M to 1.6 M (-33.33 %) |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | J | 0.00 | 8,110 | 0 | 16,224 | 24.3 K to 16.2 K (-33.33 %) |
| Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | J | 0.00 | 1,368,013 | 0 | 2,736,032 | 4.1 M to 2.7 M (-33.33 %) |
| Sep 05 2017 | CRSP | CRISPR Therapeutic ... | Novak Rodger | Chief Executive Off ... | Option Exercise | M | 1.81 | 3,853 | 6,974 | 40,826 | |
| Sep 05 2017 | CRSP | CRISPR Therapeutic ... | Novak Rodger | Chief Executive Off ... | Sell | S | 20.33 | 3,853 | 78,320 | 1,148,007 | 1.2 M to 1.1 M (-0.33 %) |
| Sep 05 2017 | CRSP | CRISPR Therapeutic ... | Novak Rodger | Chief Executive Off ... | Buy | M | 1.81 | 3,853 | 6,974 | 1,151,860 | 1.1 M to 1.2 M (+0.34 %) |
| Sep 05 2017 | CRSP | CRISPR Therapeutic ... | Novak Rodger | Chief Executive Off ... | Sell | S | 20.87 | 14,617 | 305,073 | 1,148,007 | 1.2 M to 1.1 M (-1.26 %) |